C060P: Pateclizumab Biosimilar, Anti-human LT alpha (LT-α) Antibody

Catalog No.: C060P | **Product Name:** Pateclizumab Biosimilar, Anti-human LT alpha (LT-α) Monoclonal Antibody

The research grade pateclizumab biosimilar (anti-human lymphotoxin alpha (LT-α) monoclonal antibody, mAb) for ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying biological pathways affected by pateclizumab. The research grade pateclizumab biosimilar protein is for research use only.

PRODUCT SPECIFICATIONS

Catalog No.	C060P
Product Name	Pateclizumab Biosimilar, Anti-human LT alpha (LT-α) Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Lymphotoxin-alpha, LT-α, tumor necrosis factor-beta, TNF-β, TNF beta, LTA, LT, TNFB, TNFSF1, Lymphotoxin alpha, TNLG1E
Summary	Recombinant Humanized IgG1 kappa Monoclonal Antibody. Pateclizumab Biosimilar uses the same protein sequences as the therapeutic antibody pateclizumab.
Source/Host	The anti-human lymphotoxin alpha (LT-α) monoclonal antibody pateclizumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade pateclizumab biosimilar specifically binds to the human lymphotoxin alpha (LT-α).
Applications	ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying biological pathways affected by pateclizumab.
Form Of Antibody	0.2 μM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 0.1 EU per 1 μg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade pateclizumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

REFERENCES & BACKGROUND

Pateclizumab is a recombinant humanized IgG1 kappa monoclonal antibody that specifically targets human lymphotoxin-alpha (LT-α, also known as TNF-β). Lymphotoxin-alpha is a member of the tumor necrosis factor (TNF) superfamily (TNFSF1) produced primarily by activated lymphocytes.

LT-α mediates key inflammatory and immune cell trafficking responses by interacting with TNF receptors (TNFR1 and TNFR2) as well as forming heterotrimers with lymphotoxin-beta (LT-β) to bind LT-β receptors. Neutralization of LT-α by Pateclizumab has been investigated in autoimmune and inflammatory diseases, such as rheumatoid arthritis and lymphnode organogenesis pathways.